Rezolute, Inc. (RZLT)
| Market Cap | 409.10M -44.2% |
| Revenue (ttm) | n/a |
| Net Income | -77.59M |
| EPS | -0.75 |
| Shares Out | 104.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,120,174 |
| Open | 4.250 |
| Previous Close | 4.230 |
| Day's Range | 3.900 - 4.330 |
| 52-Week Range | 1.070 - 11.457 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 9.80 (+151.28%) |
| Est. Earnings | Nov 5, 2026 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price target is $9.8, which is an increase of 151.28% from the latest price.
News
Rezolute completes enrollment in upLIFT study of ersodetug
Rezolute (RZLT) announced that the open-label Phase 3 study of ersodetug in tumor HI, or upLIFT, is now fully enrolled and topline data are expected mid-December. The company plans to…
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused ...
Rezolute Proxy statement: Proxy filing
Rezolute filed a proxy statement on October 7, 2026, providing details for shareholder voting and corporate governance matters.
Rezolute price target raised to $12 from $9 at Lake Street
Lake Street analyst Daniel Brims raised the firm’s price target on Rezolute (RZLT) to $12 from $9 and keeps a Buy rating on the shares after the company announced feedback…
Rezolute price target raised to $15 from $11 at Citizens
Citizens raised the firm’s price target on Rezolute (RZLT) to $15 from $11 and keeps an Outperform rating on the shares. Rezolute’s FDA feedback is a meaningful positive, with the…
Rezolute upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald upgraded Rezolute (RZLT) to Overweight from Neutral. The firm is positive on the FDA recommendation to hold a pre-BLA meeting for ersodetug in congenital hyperinsulinism as announced...
Rezolute announces FDA recommendation to hold pre-BLA meeting for ersodetug
Rezolute (RZLT) announced that following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI, the FDA…
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities
Rezolute initiated with a Buy at Lake Street
Lake Street analyst Daniel Brims initiated coverage of Rezolute (RZLT) with a Buy rating and $9 price target The firm’s price target reflects the opportunity for ersodetug, Rezolute’s lead clinical…
Craig-Hallum upgraded Rezolute to Buy ahead of study data
As previously reported, Craig-Hallum upgraded Rezolute (RZLT) to Buy from Hold with a price target of $7, up from $4, in anticipation of positive topline data from ersodetug’s Phase III…
Rezolute upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Albert Lowe upgraded Rezolute (RZLT) to Buy from Hold with a price target of $7, up from $4.
Rezolute price target raised to $10 from $6 at Jones
Jones raised the firm’s price target on Rezolute (RZLT) to $10 from $6 and keeps a Buy rating on the shares after the company reported Q4 results. In the open-label…
Rezolute price target raised to $10 from $5 at H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Rezolute (RZLT) to $10 from $5 and keeps a Buy rating on the shares. The company continues to target…
Rezolute reports Q4 EPS (20c), consensus (14c)
Cash, cash equivalents and investments in marketable securities were $107.8M as of June 30, compared with $167.9M as of June 30, 2025. upLIFT, a Phase 3, single-arm, open label study…
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypogl...
Rezolute Earnings release: Q4 2026
Rezolute released its Q4 2026 earnings on September 24, 2026, summarizing the period's financial results.
Rezolute Annual report: Q4 2026
Rezolute has published its Q4 2026 annual report on September 24, 2026.
Rezolute provides update on FDA review of sunRIZE study
Rezolute (RZLT) provided an update on the status of the ongoing FDA review of data from the company’s Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due…
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a ...
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemi...
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia...
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on June 26, 2026.
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenita...
Rezolute price target raised to $11, named a Best Idea at Guggenheim
Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Rezolute (RZLT) to $11 from $6 and keeps a Buy rating on the shares, which the analyst is also naming…